Molecular Therapy: Nucleic Acids (Dec 2024)

Rationally designed Campylobacter jejuni Cas9 enables efficient gene activation and base editing

  • Yuxi Chen,
  • Rui Kang,
  • Yuanling Jiang,
  • Qi Zheng,
  • Yue Yang,
  • Jiaqi Liu,
  • Guanglan Wu,
  • Weijun Zhao,
  • Zhan Li,
  • Chengxiang Peng,
  • Pengfei Zhang,
  • Fei Peng,
  • Qianyi Liu,
  • Sihui Hu,
  • Xiao Luo,
  • Guifang Wu,
  • Kaixin Cui,
  • Junjiu Huang,
  • Yongming Wang,
  • Zhou Songyang,
  • Puping Liang

Journal volume & issue
Vol. 35, no. 4
p. 102366

Abstract

Read online

Compact and adaptable CRISPR-Cas systems enable genome engineering applications in various contexts via high-efficiency delivery. The adeno-associated virus (AAV) is a widely used delivery system. One of the most compact type II-C Cas9 orthologs—CjCas9, derived from Campylobacter jejuni, is particularly appealing for AAV delivery. However, the editing efficiency of CjCas9 limits its applications. In this study, we used structure-guided protein engineering to improve the editing efficiency of CjCas9. Subsequently, we developed a miniature transcriptional activator (LDE-CjCas9-VPR) and base editors engineered from CjCas9 (LDE-CjABE and LDE-CjCBE). LDE-CjABE effectively induced genome editing in human and mouse cells. Through AAV delivery, LDE-CjABE enhanced the on-target editing efficiency, and off-target editing was not detected in the mouse retina. Therefore, the compact size and high editing efficiency of LDE-CjCas9 broadens the target scope of transcription activation and base editing toolsets for therapeutic applications.

Keywords